Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 3/20 | 0.38 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP2 | P12104 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17458590 | 0.85 | LMNA (0.44) | LMNAPOLBTP53HTR7HTR6 | |
| SCHEMBL17458530 | 0.83 | CHRM1 (0.48) | LMNAPOLBTP53FABP4HTR7 | |
| SCHEMBL17458537 | 0.82 | LMNA (0.40) | LMNAPOLBTP53HTR6ACHE | |
| SCHEMBL17458509 | 0.80 | LMNA (0.39) | LMNAPOLBTP53NTSR1ACHE | |
| SCHEMBL17458525 | 0.79 | POLB (0.44) | LMNAPOLBFABP4HTR7ACHE | |
| SCHEMBL17063383 | 0.74 | KDM4E (0.46) | ACHE | |
| SCHEMBL17063266 | 0.71 | POLB (0.50) | POLBACHE | |
| SCHEMBL17078958 | 0.70 | HTR7 (0.44) | FABP4NTSR1HTR7FABP3FABP2 | |
| SCHEMBL17079081 | 0.70 | ACHE (0.46) | HTR7ACHE | |
| SCHEMBL17063326 | 0.70 | SMN1; SMN2 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701663-B2 | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC (US) | 2017-07-11 | — | — | US | disclosed |
| EP-3172195-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | Innov17 LLC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2016-01-28 | — | — | US | disclosed |
| WO-2016014910-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | RARA, RARB, RXRA | LMNA 3352/4885HTR2A 2411/4885HTR2C 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.